DxCodebookFY2027 · Oct 1, 2026 – Sep 30, 2027

Category · FY2027

E16 Other disorders of pancreatic internal secretion

  • Header · not billable

E16 is not billable. The category heads 10 billable codes in FY2027, grouped under 8 subdivisions.

Index → code

  • Glycopenia → E16.2
  • Hypergastrinemia → E16.4
  • Ellison-Zollinger syndrome → E16.4

Where it sits

  1. Chapter 4 Endocrine, nutritional and metabolic diseases (E00-E89)
  2. E15-E16 Other disorders of glucose regulation and pancreatic internal secretion (E15-E16)
  3. E16 Other disorders of pancreatic internal secretion
Billable codes
10
Subdivisions
8
CC / MCC codes
0 / 0
HCC V28 codes
0
New FY2027
0
Index entries
53

Codes in E16

  1. E16.0
    Drug-induced hypoglycemia without coma
    Billable
    Excludes1 1, Use additional code 2

    Excludes1

    • diabetes with hypoglycemia without coma (E09.649) E09.649

    Use additional code

    • code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5) T36 T50
    • code for hypoglycemia level, if applicable (E16.A-) E16.A
  2. E16.1
    Other hypoglycemia
    Billable
    Inclusion terms 4, Excludes1 3, Use additional code 1

    Inclusion terms

    • Functional hyperinsulinism
    • Functional nonhyperinsulinemic hypoglycemia
    • Hyperinsulinism NOS
    • Hyperplasia of pancreatic islet beta cells NOS

    Excludes1

    Use additional code

    • code for hypoglycemia level, if applicable (E16.A-) E16.A
  3. E16.2
    Hypoglycemia, unspecified
    Billable
    Excludes1 1, Use additional code 1

    Excludes1

    Use additional code

    • code for hypoglycemia level, if applicable (E16.A-) E16.A
  4. E16.3
    Increased secretion of glucagon
    Billable
    Inclusion terms 1

    Inclusion terms

    • Hyperplasia of pancreatic endocrine cells with glucagon excess
  5. E16.4
    Increased secretion of gastrin
    Billable
    Inclusion terms 3

    Inclusion terms

    • Hypergastrinemia
    • Hyperplasia of pancreatic endocrine cells with gastrin excess
    • Zollinger-Ellison syndrome
  6. E16.8
    Other specified disorders of pancreatic internal secretion
    Billable
    Inclusion terms 4

    Inclusion terms

    • Increased secretion from endocrine pancreas of growth hormone-releasing hormone
    • Increased secretion from endocrine pancreas of pancreatic polypeptide
    • Increased secretion from endocrine pancreas of somatostatin
    • Increased secretion from endocrine pancreas of vasoactive-intestinal polypeptide
  7. E16.9
    Disorder of pancreatic internal secretion, unspecified
    Billable
    Inclusion terms 2

    Inclusion terms

    • Islet-cell hyperplasia NOS
    • Pancreatic endocrine cell hyperplasia NOS
  8. E16.A
    Hypoglycemia level
    Header
  9. E16.A1
    Hypoglycemia level 1
    Billable
    Inclusion terms 1

    Inclusion terms

    • Decreased blood glucose level 1
  10. E16.A2
    Hypoglycemia level 2
    Billable
    Inclusion terms 1

    Inclusion terms

    • Decreased blood glucose level 2
  11. E16.A3
    Hypoglycemia level 3
    Billable
    Inclusion terms 1

    Inclusion terms

    • Decreased blood glucose level 3

Sources of each column.

Instructions

Notes that also apply

Chapter 4 instructions (Notes 1, Excludes1 1): printed on the chapter 4 page.

Index entries

  • Hyperinsulinism (functional) → E16.1
  • Glycopenia → E16.2
  • Hypoglycemia (spontaneous) → E16.2
  • McQuarrie's syndrome (idiopathic familial hypoglycemia) → E16.2
  • Ellison-Zollinger syndrome → E16.4
  • Hypergastrinemia → E16.4
  • Zollinger-Ellison syndrome → E16.4
  • Hypoglycemia (spontaneous)drug-induced → E16.0
  • Hypoglycemia (spontaneous)due to insulin → E16.0
  • Hypoglycemia (spontaneous)iatrogenic → E16.0
  • Reactionhypoglycemic, due to insulin → E16.0
  • Encephalopathy (acute)posthypoglycemic (coma) → E16.1 [G94]
  • Hyperinsulinism (functional)ectopic → E16.1
  • Hypoglycemia (spontaneous)functional, nonhyperinsulinemic → E16.1
  • Hypoglycemia (spontaneous)infantile → E16.1
  • Hypoglycemia (spontaneous)reactive (not drug-induced) → E16.1
  • Decrease (d)glucose → E16.2
  • Encephalopathy (acute)hypoglycemic → E16.2
  • Syndromehypoglycemic (familial) (neonatal) → E16.2
  • SyndromeMcQuarrie's → E16.2
  • Abnormal, abnormality, abnormalitiesglucagon secretion → E16.3
  • Excess, excessive, excessivelyglucagon → E16.3
  • Hypersecretionglucagon → E16.3
  • Abnormal, abnormality, abnormalitiesgastrin secretion → E16.4
  • Hypersecretiongastrin → E16.4
  • Disorder (of)pancreatic internal secretion → E16.9
  • Hyperplasia, hyperplasticpancreatic islet cells → E16.9
  • Encephalopathy (acute)in (due to) (with)hyperinsulinism → E16.1 [G94]
  • Hyperinsulinism (functional)withencephalopathy → E16.1 [G94]
  • Hyperplasia, hyperplasticpancreatic islet cellsbeta → E16.1
  • Decrease (d)bloodglucose → E16.2
  • Findings, abnormal, inconclusive, without diagnosisblood sugarlow (transient) → E16.2
  • Polyneuropathy (peripheral)in (due to)hypoglycemia → E16.2 [G63]
  • Sugarbloodlow (transient) → E16.2
  • Abnormal, abnormality, abnormalitiessecretionglucagon → E16.3
  • Increase, increasedsecretionglucagon → E16.3
  • Abnormal, abnormality, abnormalitiessecretiongastrin → E16.4
  • Increase, increasedsecretiongastrin → E16.4
  • Disorder (of)pancreatic internal secretionspecified NEC → E16.8
  • Hyperplasia, hyperplasticpancreatic islet cellsalpha → E16.8

13 more, longer entries are not listed; the search box finds them by word.

NCHS Alphabetic Index. Index first, then the Tabular List.

Hierarchy